The short version
21 companies supply this market — deep enough that no single failure threatens the supply.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Levocetirizine Dihydrochloride
Levocetirizine Dihydrochloride · LEVOCETIRIZINE DIHYDROCHLORIDE 5 mg/1 · Tablet · Oral · Camber Pharmaceuticals, Inc.
NDC 31722-0551-18 · 180 TABLET in 1 BOTTLE · ANDA · View full market →
Medicare Part D
All Part D pricing →Matched to CMS's representative package for this drug (NDC 31722-0551-90) — same generic, strength, and dosage form. CMS prices one NDC per drug concept, not every package.
ⓘ How this was built
Data sources
- CMS quarterly Prescription Drug Plan Formulary & Pricing files (SPUF)
Method
Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
Plans pay at point of saleⓘ
$0.1725per unit
middle half $0.1272–$0.2715 · 5,496 plans · Apr 1, 2026
Est. net of rebatesⓘ
≈ $0.1725
generic — rebates are minimal, so net ≈ gross
Coverage & restrictions
100%of plans cover it
tier 2 · prior auth 0% · step therapy 0% · qty limit 74%
*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 10 quarters since 2024.
NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
90-day shortage risk (model v2)
0.1%chance of a new FDA shortage posting for levocetirizine dihydrochloride (oral solid) in the next 90 days
sole-source market · price up 6% YoY
For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.
Backtested statistical model over the whole market, not this package alone. Model details →
Where it's made
- analysis · manufacture
- Hetero Labs LimitedIndiamanufacture
Establishments this product's FDA label declares, located via FDA registration data. How we built this →
Regulatory
- Application
- ANDA091264
- TE code
- AB
- Approval date
- Jun 29, 2012
- Patents / exclusivity
- None on file
Shortage history
No FDA shortage reports for this drug or its presentations.
Recalls (this NDC)
No enforcement reports list this package NDC.
Manufacturers of Levocetirizine Dihydrochloride (Tablet)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| A-S Medication Solutions | LEVOCETIRIZINE DIHYDROCHLORIDE 5 mg/1 | Jul 15, 2026 | Sep 3, 2026 |
| Bryant Ranch Prepack | LEVOCETIRIZINE DIHYDROCHLORIDE 5 mg/1 | Jul 15, 2026 | Sep 3, 2026 |
| Chattem, Inc. | LEVOCETIRIZINE DIHYDROCHLORIDE 5 mg/1 | Jul 15, 2026 | Sep 3, 2026 |
| Proficient Rx LP | LEVOCETIRIZINE DIHYDROCHLORIDE 5 mg/1 | Jul 15, 2026 | Sep 3, 2026 |
| Camber Pharmaceuticals, Inc. | LEVOCETIRIZINE DIHYDROCHLORIDE 5 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Glenmark Pharmaceuticals Inc., USA | LEVOCETIRIZINE DIHYDROCHLORIDE 5 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Golden State Medical Supply, Inc. | LEVOCETIRIZINE DIHYDROCHLORIDE 5 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Micro Labs Limited | LEVOCETIRIZINE DIHYDROCHLORIDE 5 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| NCS HealthCare of KY, LLC dba Vangard Labs | LEVOCETIRIZINE DIHYDROCHLORIDE 5 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| NuCare Pharmaceuticals, Inc. | LEVOCETIRIZINE DIHYDROCHLORIDE 5 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| NuCare Pharmaceuticals,Inc. | LEVOCETIRIZINE DIHYDROCHLORIDE 5 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Opella Healthcare International Sas | LEVOCETIRIZINE DIHYDROCHLORIDE 5 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| PD-Rx Pharmaceuticals, Inc. | LEVOCETIRIZINE DIHYDROCHLORIDE 5 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Preferred Pharmaceuticals, Inc. | LEVOCETIRIZINE DIHYDROCHLORIDE 5 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| ScieGen Pharmaceuticals, Inc. | LEVOCETIRIZINE DIHYDROCHLORIDE 5 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Synthon Hispania S.L. | LEVOCETIRIZINE DIHYDROCHLORIDE 5 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Velocity Pharma Llc | LEVOCETIRIZINE DIHYDROCHLORIDE 5 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Vensun Pharmaceuticals, Inc. | LEVOCETIRIZINE DIHYDROCHLORIDE 5 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Westminster Pharmaceuticals, LLC | LEVOCETIRIZINE DIHYDROCHLORIDE 5 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Yyba Corp | LEVOCETIRIZINE DIHYDROCHLORIDE 5 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Northwind Health Company, LLC | LEVOCETIRIZINE DIHYDROCHLORIDE 5 mg/1 | Jul 15, 2026 | Aug 28, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "Levocetirizine Dihydrochloride — NDC 31722-0551-18," retrieved September 3, 2026, https://drugdashboards.com/drug/31722055118.
Free to cite with attribution — see how the data is put together.